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Abstract 
Background.  The role of external beam radiation in the treatment of melanoma remains 
controversial. While melanoma is no longer considered radio-resistant, the indications and 
outcomes for adjuvant radiation therapy in melanoma patients are still evolving.    
Methods.  A retrospective review was conducted of patients diagnosed with malignant 
melanoma and treated with postoperative radiation therapy at the University of Kansas Medical 
Center.  
Results.  Forty-five patients (27 male; 18 female) with a diagnosis of malignant melanoma were 
treated with external beam radiation therapy for curative intent between 1985 and 2005.  Local 
control at the treatment site was achieved in 42 of 45 patients and was maintained in 35 patients 
(78%) at a median follow-up of 14 months.  The median time for freedom from any disease 
progression was 12 months. 
Conclusions.  Radiation therapy is an effective option for management of patients with 
malignant melanoma with local control being achieved and maintained in the majority of 
patients.   KJM 2008; 2(1):1-7. 
Introduction 
The role of radiation in the treatment of 
malignant melanoma often is palliative to 
relieve the symptoms of widespread 
metastatic disease.  However, there is a 
possible role of radiation in the curative 
setting.  While surgical resection remains 
the standard primary treatment, a significant 
number of completely excised lesions will 
recur, especially in patients with high-risk 
features.   
Some of the adverse prognostic factors 
for overall survival include tumor thickness 
and ulceration1, while extra-capsular 
extension, cervical lymph node involvement, 
and excised lymph nodes larger than 3 cm 
are prognostic factors for lymph node 
failure.2   Patients who test positive for these  
 
 
factors can have local failure rates after 
surgery alone as high as 50%.3  These high 
local failure rates  have prompted  the search 
for ways to achieve better local control.  
Although interferon initially looked 
promising4, further studies have not shown 
this modality to be as beneficial as first 
thought.5  
Radiation therapy is another option in 
the adjuvant treatment of malignant 
melanoma. Several studies have examined 
the role of radiation in the non-palliative 
setting.  The results of these studies 
indicated that adjuvant radiotherapy may be 
beneficial for patients with high risk 
features, both for reducing failure at the 
primary site6,7 and failure in the lymph node 
basins7-13. 
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This report will examine the results of 
and possible indications for post-operative 
radiation therapy in the management of 
patients with malignant melanoma.  
 
Methods 
A retrospective review of the malignant 
melanoma patients receiving radiation 
therapy at the University of Kansas Medical 
Center (KUMC) between 1985 and 2005 
was conducted.  Approval for this study was 
granted by the KUMC Institutional Review 
Board.   
The KUMC tumor registry identified all 
patients with a diagnosis of melanoma who 
received radiation as a component of their 
treatments.  Patients who were treated for 
palliation and those who received radiation 
by means other than external beam (such as 
brachytherapy) were excluded from this 
review.  After exclusion, 45 patients and a 
total of 47 treatments were available for 
analysis.  One individual received three 
separate treatments over a time span of 19.2 
months; only the first treatment is 
considered. 
Statistical analysis was performed with 
SPSS for Windows (Release 16.0, SPSS Inc, 
Chicago, IL). Categorical variables were 
summarized by frequencies and percentages, 
and quantitative variables were summarized 
by medians and ranges. The duration of 
follow-up was calculated from the time of 
completion of radiation treatment until the 
date of event or last known follow-up. Time 
to event (overall survival, freedom from 
disease progression, and freedom from local 
recurrence) was analyzed by Kaplan-Meier 
survival plots and univariate analysis by the 
log-rank test. 
For univariate analysis, categorical 
variables were compared by the log-rank test 
and/or continuous variables by Cox 
proportional hazards analysis. Multivariate 
analysis by Cox regression analysis was then 
performed. Probability values of p<0.05 
were considered to be statistically 
significant. No corrections for multiple 
comparisons were made. 
 
Results 
The study population consisted of 27 
males and 18 females with a median age of 
60.3 years (range 14 to 85 years).  All 
patients had surgery as the initial component 
of their therapy.  The primary tumor sites 
were head and neck (16 patients, 36%), 
upper extremity (6, 13%), lower extremity 
(15, 33%), and trunk (6, 13%); with two 
patients (4%) having an unknown site.  The 
tumor stage and nodal status at diagnosis is 
provided in Table 1.  
All patients had surgery as the initial 
component of their therapy prior to 
radiotherapy. Thirty-three of the radiation 
treatments (73%) were to the site of resected 
primary disease; of which 12 (27%) were at 
the time of original presentation and 21 
(47%) were at the time of recurrence. 
Lymph node regions were included in the 
treatments of 26 patients (57%), 9 (20%) at 
the time of original presentation and 17 
(38%) at the time of recurrence. Fifteen 
patients (33%) received radiation treatment 
to both the primary site and the lymph 
nodes.  One patient (2%) was treated later to 
another site other than lymph nodes. 
 
Table 1.  Tumor stage and nodal status at 
diagnosis. 
*Tx denotes a primary tumor that could not 
be assessed.  
**One patient was M1a. 
Nodal Status Tumor 
Stage 0 1 2 3 Total 
Tx* 4** 2 1  7 
T1 7    7 
T2 5 2 1  8 
T3 6 1   7 
T4 6 4 3 3 16 
Total 28 9 5 3 45 
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External beam radiation varied in terms 
of both dose per fraction and fractions per 
week. The majority of patients (28, 60%) 
were treated on a daily basis, Monday 
through Friday, for five fractions per week. 
Other fractionation schemes included three 
times per week (9 patients, 20%), twice per 
week (7 patients, 16%), and one patient was 
treated twice daily (10 times per week). 
Dose also was variable with 33 treatments at 
four gray (Gy) per fraction, seven treatments 
at six Gy per fraction, and five treatments at 
2-3 Gy per fraction. Total dose ranged from 
24 to 66 Gy, but was centered at 32 Gy.  
Twenty-three (51%) of the patients were 
treated with eight fractions of four Gy. 
Moreover, these eight fractions were 
delivered over an interval that included one 
weekend, for a total treatment time of nine 
days.  Four others were treated over one 
additional weekend for a total treatment time 
of 11 days. 
Systemic therapies included interferon 
and chemotherapy. Eight (18%) patients 
received interferon as an initial aspect of 
treatment and five (11%) received interferon 
after recurrence or progression. Chemo-
therapy was used initially in two (4%) 
patients and as secondary treatment in six 
(13%) patients.  
The median follow-up from completion 
of radiation treatment for all patients 
analyzed was 23 months with a range of 2.4 
to 136 months. At last follow-up, 24 patients 
were alive with a median follow-up of 32 
months (range 13 to 136 months).  For the 
21 patients who had died, the median 
follow-up was 13 months with a range of 2.4 
to 44 months. Of the 24 patients alive, 11 
(24%) had evidence of disease and 13 (29%) 
had no evidence of disease.  Two expired 
patients and one patient still alive never 
achieved disease-free status after completion 
of treatment.   
The median disease free survival (DFS) 
for all patients was 12 months (Figure 1). 
For 26 patients (including the three with 
persistent disease) that had evidence of 
malignancy, the median time to progression 
was six months. Of the three patients that 
had residual local disease after treatment, 
one had persistent stable disease but 
experienced distant failure and died at seven 
months; two patients had progressive local 
disease but no distant failure (one dead at 
seven months and one alive at 13 months). 
An additional seven patients had a 
subsequent recurrence within the radiation 
field; all but one also had distant failure 
concurrent with the local failure.  For the 
seven local failures, the median time to 
disease recurrence was 12 months. Overall, 
local control was achieved and maintained 
in 35 patients (78%), with a median time to 
recurrence not being reached (Figure 1).  
A total of 26 patients had a recurrence 
outside the radiation field with a median 
time to distant failure of seven months.  Of 
the 26 distant failures, six patients (as 
described above) had concurrent local 
failures leaving 21 patients with isolated 
distant failures.  The median time for failure 
for these 21 patients was nine months. The 
most common site of distant failure was the 
central nervous system with 13 patients or 
half of all distant failures.  
 
Figure 1. Comparison between Freedom 
from Local Recurrence (dashed line) and 
Freedom from Disease Progression (solid 
line).  The triangles indicate times at which 
patients were censored.  
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Table 2.  Analysis of factors associated with outcome. 
*Median times for Freedom from Local Recurrence were not reached except for the sub-groups 
of Total dose > 32 Gy and Treatment time > 12 days, both of which were 12 months. 
**Global analysis for difference: aComparison between <32 Gy and 32 Gy; bComparison between 
32 Gy and >32 Gy. 
 
Multiple factors were examined for a 
possible effect on freedom from disease 
progression (Table 2). The only factors that 
were statistically significant predictors by 
univariate analysis were gender (p=0.010), 
with males doing better, and total dose 
(p=0.010 overall), with better outcome being 
exhibited when the dose was exactly 32 Gy, 
compared to doses <32 Gy (p=0.090) or >32 
Gy (p=0.002). There were no statistically 
significant differences in clinical 
presentation (age, T-stage, nodal status, 
histology, etc.) between the three dose 
groups (<32 Gy, 32 Gy, >32 Gy).  There 
was  a  marginal influence  of total treatment  
 
time, with patients treated in 12 days or less 
exhibiting better outcome than patients 
whose treatment required longer than 12 
days (p=0.042). By multivariate Cox 
regression analysis, both total dose 
(p=0.006) and gender (p=0.019) were 
retained as independent predictors of 
freedom from disease progression.  
Similarly, factors influencing freedom 
from local recurrence were examined (Table 
2). As with freedom from disease 
progression, total dose influenced the 
outcome (p=0.001 overall), with patients 
that received >32 Gy exhibiting a poorer 
outcome (6/11 patients recurring,  55%) than 
Freedom from 
Disease Progression 
Freedom from 
Local Recurrence*  Factor 
Number 
of 
Patients Median, 
months 
p value p value 
Male 27 17 Gender 
Female 18 6 0.010 0.078 
Primary 
radiotherapy 
16 12 Prior treatment 
Secondary 
radiotherapy 
29 12 0.90 0.77 
Positive  25 9 Lymph nodes at 
time of 
treatment 
Negative 20 14 0.19 0.39 
< 60 years 19 9 Age 
> 60 years 26 12 0.79 0.45 
< 32 Gy 11 6 
   32 Gy 23 20 
Total dose 
> 32 Gy 11 7 
 0.090a 
0.010** 
 0.002b 
0.26a 
      0.001** 
0.010b 
Tis-T2 (0-2 mm) 22 10 Depth (initial) 
T3-T4 (> 2 mm) 23 10 0.77 1.0 
Positive 17 14 Lymph nodes at 
initial diagnosis Negative 28 12 
0.96 
 
0.64 
 
≤ 12 days 24 14 Treatment time  
> 12 days 21 9 0.042 0.001 
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patients that received exactly 32 Gy (4/23 
patients, 17%), which was statistically 
significantly different (p=0.010).  However, 
patients that received <32 Gy actually 
exhibited a better outcome (none of the 11 
patients recurred) than patients who received 
32 Gy, although the difference was not 
statistically significant (p=0.26).  Only for 
the >32 Gy group was a median time to 
event reached (12 months). Also, overall 
treatment time was a factor (p=0.010) with 
patients treated in less than 12 days doing 
better than patients whose treatment 
required >12 days. Again, only for the latter 
group was median time to event reached (12 
months).  By multivariate Cox regression 
analysis, the overall treatment time was 
retained (p<0.001) and gender (p=0.050) 
was added as independent predictors of 
freedom from local recurrence.  However, if 
overall treatment time was not included, 
then only total dose was identified as a 
predictor (p=0.001). 
 
Discussion 
 As with any retrospective review, these 
data need to be interpreted with caution. 
There is an inherent bias in patients that are 
referred for adjuvant radiation treatment and 
also patients who elect to undergo 
radiotherapy. Despite these limitations, 
outcomes data such as these are valuable in 
estimating the possible benefit to patients in 
terms for local control and overall-survival.  
 Our outcomes, with a median time for 
freedom from disease progression and DFS 
of 12 months and a local control rate of 
78%, were consistent with some of the 
ranges reported in the literature.  Stevens et 
al.6 found a local recurrence rate of 11% and 
median disease free survival of 25 months in 
174 high-risk patients.  Ang et al.7 reported a 
5-year 88% local control rate and survival 
rate of 47%, with a hypofractionated 
treatment regiment for high-risk head and 
neck melanoma.  Ballo et al.8 reported on 
treatment of 89 consecutive patients with 
axillary radiation, finding a 13% failure rate 
in the treated axilla and in a separate report 
of 160 patients with cervical radiation, a 9% 
local failure rate at 10 years.9  Cooper et 
al.10 had a five-year actuarial failure rate of 
16% in a review of 40 patients treated with 
elective post-operative radiation. Corry et 
al.11 described a 74% treatment failure rate 
at five years in their treatment of high-risk 
nodal areas.  One explanation for the wide 
range of results for adjuvant radiation was 
the different institutional indications for 
treatment, thus different patient populations.  
 We analyzed the data to see if certain 
patient subsets had better outcomes. For 
freedom from disease progression, gender 
was a significant factor, with males having a 
more favorable prognosis. This finding was 
contrary to other authors who have found 
male gender to be an adverse prognostic 
factor.1 This result may reflect a type I 
statistical error due to the small number of 
patients in our study. In addition, the total 
dose delivered had a significant impact on 
outcome, with those patients receiving 32 
Gy in eight fractions of four Gy each (51% 
of all patients) exhibiting superior outcomes 
compared to patients that received total 
doses less than or greater than 32 Gy.   
For freedom from local recurrence, 
similar findings were obtained, with a better 
prognosis for those patients treated with 32 
Gy than for those patients that received >32 
Gy total dose.  These analyses are 
confounded by the fact that a large 
proportion (51%) of patients were treated 
with the same regimen, eight fractions of 
four Gy for a total dose of 32 Gy.  Of the ten 
additional patients treated with four Gy 
fractions, two received a total dose <32 Gy 
and eight received a total dose >32 Gy.  
Likewise, of the 23 patients that received a 
total dose of 32 Gy, all but four required a 
total treatment time of 12 days or less.  
Thus, there were close correlations between 
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total dose, dose per fraction, and treatment 
time, with the consequent potential for one 
variable to confound the impact of another 
variable in the analysis.  None-the-less, the 
results suggested that overall the KUMC 
“standard” regimen of 8 x 4 Gy in less than 
two weeks was effective for achieving and 
maintaining local control.   
 Many institutions have reported results 
using a hypofractionated (giving the same 
total dose of radiation over fewer fractions) 
radiation scheme, typically 30 Gy in five 
twice-weekly fractions6-10 although this has 
not been proven to be superior to more 
conventional fractionation schemes. Chang 
et al.15 retrospectively compared hypo-
fractionation and conventional fractionation 
in 56 cutaneous melanoma patients and did 
not find any difference in the two regimens. 
While a larger series may reveal a patient 
subset that benefits from higher overall 
treatment dose, caution should be used in 
higher fraction doses since this will 
predispose patients to a greater degree of 
radiation side effects, especially 
lymphedema.  
  Post-operative radiation therapy appears 
to provide good local control but it may not 
affect survival since the majority of patients 
have distant failures despite good local 
control. In this series of patients, there were 
no isolated local failures. The implications 
for future treatment directions should thus 
focus on more systemic therapies.  While it 
is possible that more aggressive use of 
radiation for the initial primary tumors and 
lymph node basins could destroy 
microscopic disease before it has a chance to 
spread distantly, it is possible that such 
treatment would only provide improved 
local control and that patients would 
eventually succumb to distant failures.   
 While a randomized trial would give the 
best level of evidence for the usefulness of 
postoperative radiation, our data indicated 
that adjuvant radiation in a post-operative 
setting appears to reduce local recurrence 
and should be considered for patients with 
malignant melanoma at high risk for local 
failure.  
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